CA3267265A1 - Promédicaments, formulations et procédés associés - Google Patents

Promédicaments, formulations et procédés associés

Info

Publication number
CA3267265A1
CA3267265A1 CA3267265A CA3267265A CA3267265A1 CA 3267265 A1 CA3267265 A1 CA 3267265A1 CA 3267265 A CA3267265 A CA 3267265A CA 3267265 A CA3267265 A CA 3267265A CA 3267265 A1 CA3267265 A1 CA 3267265A1
Authority
CA
Canada
Prior art keywords
prodrugs
formulations
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3267265A
Other languages
English (en)
Inventor
Peter Jarrett
Rami El-Hayek
Original Assignee
Ocular Therapeutix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocular Therapeutix Inc filed Critical Ocular Therapeutix Inc
Publication of CA3267265A1 publication Critical patent/CA3267265A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA3267265A 2022-10-14 2023-10-13 Promédicaments, formulations et procédés associés Pending CA3267265A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263416292P 2022-10-14 2022-10-14
US63/416,292 2022-10-14
PCT/US2023/035121 WO2024081410A1 (fr) 2022-10-14 2023-10-13 Promédicaments, formulations et procédés associés

Publications (1)

Publication Number Publication Date
CA3267265A1 true CA3267265A1 (fr) 2024-04-18

Family

ID=90670179

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3267265A Pending CA3267265A1 (fr) 2022-10-14 2023-10-13 Promédicaments, formulations et procédés associés

Country Status (7)

Country Link
EP (1) EP4601642A1 (fr)
JP (1) JP2025534605A (fr)
CN (1) CN119947722A (fr)
AU (1) AU2023360240A1 (fr)
CA (1) CA3267265A1 (fr)
MX (1) MX2025003792A (fr)
WO (1) WO2024081410A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20260040A1 (es) 2023-04-11 2026-01-09 Ocular Therapeutix Inc Implante ocular que contiene un inhibidor de la tirosina cinasa

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI700085B (zh) * 2015-06-22 2020-08-01 新源生物科技股份有限公司 酪胺酸激酶抑制劑之眼用調配物的用途
US20210078970A1 (en) * 2019-08-30 2021-03-18 Risen (Suzhou) Pharma Tech Co., Ltd. Prodrugs of the tyrosine kinase inhibitor for treating cancer
CN118119599A (zh) * 2021-10-15 2024-05-31 视尔普斯眼科公司 阿昔替尼前药

Also Published As

Publication number Publication date
CN119947722A (zh) 2025-05-06
MX2025003792A (es) 2025-05-02
AU2023360240A1 (en) 2025-04-03
JP2025534605A (ja) 2025-10-17
WO2024081410A1 (fr) 2024-04-18
EP4601642A1 (fr) 2025-08-20

Similar Documents

Publication Publication Date Title
EP4028020A4 (fr) Promédicaments antiviraux et formulations de ceux-ci
EP4110066A4 (fr) Formulations et leurs utilisations
EP3946320A4 (fr) Conjugués liés à hsp90 et formulations de ceux-ci
EP4329879A4 (fr) Nouvelles compositions de n,n-diméthyltryptamine et méthodes
EP4007590A4 (fr) Formulations comprenant du dihydrohonokiol
CA3267265A1 (fr) Promédicaments, formulations et procédés associés
CA3261864A1 (fr) Nouvelles formulations agrochimiques
EP4145000A4 (fr) Soufflante
EP4164619A4 (fr) Méthodes de traitement et formulations
HK40125882A (en) Prodrugs, formulations and methods thereof
HK40129881A (zh) 贝祖拉替尼制剂
EP4093278A4 (fr) Formulations d'amélioration esthétique et procédés associés
CA3286640A1 (fr) Promédicaments, compositions de promédicaments et procédés associés
CA3277614A1 (fr) Formulations de bezuclastinib
AU2023903711A0 (en) Formulations
CA3301137A1 (fr) Formulations d'arénavirus, procédés et utilisations associés
AU2020903873A0 (en) Lymph-Targeting Formulations
AU2020901866A0 (en) Immugenic formulations
HK40105577A (en) Stable ruc-4 formulations
HK40080132A (en) Novel formulations and methods
HK40100836A (en) Formulations, methods, kits, and dosage forms
HK40084380A (zh) 制剂及其用途
HK40119183A (zh) 尼古丁制剂
CA3294652A1 (fr) Nouvelles formulations
AU2024307383A1 (en) Novel formulations

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20250310

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20250415

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250616

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250616

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20250616

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250616

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250616

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250616

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251003

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251003